Motilin / Motilin agonists

Motilin is released cyclically from duodenal M-cells during fasting and drives phase III of the migrating motor complex — the sweeping contractions that clear residual food and bacteria from the stomach and small bowel between meals. It acts on the motilin receptor (GPR38) on cholinergic enteric neurons and on gastric smooth muscle. Erythromycin, discovered by accident to be a motilin receptor agonist, is the only clinically used member of the class and reliably accelerates gastric emptying at sub-antimicrobial doses. Its fatal flaw is rapid tachyphylaxis: receptor downregulation blunts the effect within days to weeks. Purpose-built motilides were developed to escape that problem — ABT-229 and mitemcinal both failed, and camicinal (GSK962040) showed promising phase 2 gastric emptying and even critical-care feeding data before development stalled. Loss of interstitial cells of Cajal in advanced gastroparesis also limits how much any prokinetic can achieve.

Targets: Motilin receptor (GPR38), Cholinergic enteric neurons, Gastric antral smooth muscle, Migrating motor complex phase III

• · Roughly 1.5 to 3 mg/kg — commonly 100-250 mg IV. This is a rescue and short-term measure; tachyphylaxis makes it useless as a chronic strategy.
• · 50-250 mg per dose, deliberately below antimicrobial dosing. Efficacy typically fades within 2-4 weeks. Cycling on and off, or reserving it for flares, is the usual workaround.
• · 50 mg once daily was the dose showing accelerated gastric emptying in phase 2 diabetic gastroparesis and improved enteral feed tolerance in critically ill patients. Development has not progressed to approval.

Work out your exact syringe units →

• very commonAbdominal cramping and nausea— The strong antral contractions are the point, and also the problem.
• very commonTachyphylaxis — loss of effect within weeks— The defining limitation of the entire class.
• commonAntimicrobial resistance and microbiome disruption— Even at sub-antimicrobial doses, chronic macrolide exposure selects for resistance.
• commonDrug interactions via CYP3A4 inhibition— Erythromycin is a potent CYP3A4 inhibitor and this is where most of its serious adverse events come from.
• uncommonQT prolongation— Erythromycin is a well-established QT-prolonging agent; risk multiplies with other QT drugs or electrolyte disturbance.

• Mechanical gastric outlet or bowel obstruction — never give a prokinetic against an obstruction.
• Congenital or acquired long QT syndrome, or concurrent QT-prolonging drugs, for erythromycin specifically.
• Concurrent use of drugs heavily dependent on CYP3A4, such as certain statins and ergot alkaloids.

• conflictstatins — Erythromycin's CYP3A4 inhibition raises simvastatin and lovastatin levels sharply, with real rhabdomyolysis risk.
• conflictqt-prolonging-drugs — Additive QT prolongation with antipsychotics, ondansetron, fluoroquinolones and class III antiarrhythmics.
• conflictglp-1-agonists — GLP-1 drugs slow gastric emptying — pharmacologically the exact opposite of what a motilin agonist is for. This combination is increasingly common and increasingly counterproductive.
• synergymetoclopramide — Different prokinetic mechanisms are sometimes combined in refractory gastroparesis, at the cost of stacked side effects.

• · Gastric emptying scintigraphy at baseline if the diagnosis is not already established.
• · ECG for QTc when using erythromycin, particularly in older patients or those on other QT drugs.
• · Symptom scores and nutritional status; watch for the effect fading around week 2-4.

Erythromycin is an approved antibiotic used off-label as a prokinetic. Camicinal, mitemcinal and ABT-229 are investigational or discontinued. Native motilin has no therapeutic form.

• Camicinal (GSK962040) phase 2 trial in diabetic gastroparesis (trial)
• Sanger, motilin receptor agonists and gastric prokinetic drug development (review)
• ACG clinical guideline on gastroparesis, 2022 (guideline)

Motilin is the hormone of the fasting gut. It is released cyclically from duodenal M-cells roughly every 90 to 120 minutes between meals, and each pulse initiates phase III of the migrating motor complex — the powerful, propagating contraction sweep that clears residual food, mucus and bacteria out of the stomach and small bowel. This is the gut's housekeeping cycle. It stops when you eat and resumes when you stop. Motilin acts on the motilin receptor (GPR38, MLNR) expressed on cholinergic enteric neurons and on gastric antral smooth muscle. Receptor activation facilitates acetylcholine release from those neurons, which is why the effect is a coordinated propulsive contraction rather than simple muscle tone. That neuronal localisation matters clinically: the drug amplifies an existing neural circuit rather than directly squeezing muscle, so it needs the circuit to be intact. Erythromycin's motilin agonism was discovered by accident — patients on erythromycin reported abdominal cramping and it turned out the macrolide ring binds GPR38. At sub-antimicrobial doses it reliably accelerates gastric emptying, and intravenously it is fast enough to use as a rescue for acute gastroparesis or to help place a feeding tube. The defining problem is tachyphylaxis. Continuous motilin receptor stimulation drives receptor downregulation, and the prokinetic effect fades within about two to four weeks. This is not a quirk of erythromycin; it appears to be a property of sustained agonism at this receptor. Every attempt to solve it with a purpose-built agonist has failed. ABT-229 failed and in some analyses worsened symptoms. Mitemcinal failed. Camicinal produced genuinely positive phase 2 data — accelerated gastric emptying in type 1 diabetics with slow emptying, improved enteral feed tolerance in critically ill patients, and confirmed effects on human gastroduodenal manometry — and then development stalled. There is a second, deeper reason this class underperforms. In advanced gastroparesis the interstitial cells of Cajal, the pacemaker cells that generate the slow wave, are progressively lost. No amount of receptor agonism restores a pacemaker that is not there. Prokinetics work best in the patients who need them least. The practical implication of tachyphylaxis is the one thing worth acting on: use erythromycin intermittently. A two to four week course during a flare, then a break to let receptor expression recover, is a rational strategy. Continuous daily dosing guarantees you will lose the effect and keep the QT risk, the CYP3A4 interactions and the resistance selection.

Tachyphylaxis is the whole story. Erythromycin works, then stops working, usually within two to four weeks, and people respond by increasing the dose — which increases cramping, resistance selection, CYP3A4 interaction burden and QT risk while doing nothing about the receptor downregulation that caused the problem. The correct response is to stop and cycle. The second failure is treating symptoms without establishing the diagnosis. A substantial fraction of people treated for gastroparesis have functional dyspepsia, rumination syndrome or cannabinoid hyperemesis instead, and none of those respond to a motilin agonist. Gastric emptying scintigraphy is worth doing once. The third is the QT problem, which is under-appreciated because erythromycin feels like a familiar old antibiotic. The gastroparesis population vomits, so it is hypokalaemic and hypomagnesaemic; it takes ondansetron, which prolongs QT; and it often takes antipsychotics as antiemetics, which also prolong QT. Adding a fourth QT-prolonging factor to that is how you get an arrhythmia. The fourth is chronic macrolide exposure driving resistance and microbiome disruption. Sub-antimicrobial dosing does not mean sub-selective — it may be worse for resistance selection than full dosing. The fifth is giving a prokinetic against a mechanical obstruction, which is contraindicated and dangerous. Distinguish gastroparesis from gastric outlet obstruction before starting. The sixth is expecting too much. In advanced disease the interstitial cells of Cajal are lost, and no receptor agonist restores a missing pacemaker.

1. 100 mgAcute rescue — Erythromycin 100-250 mg intravenously (roughly 1.5 to 3 mg/kg) infused over 20-30 minutes, typically 30-60 minutes before a feed or a feeding-tube placement. This is the strongest use case for the whole class — a single dose, immediate effect, no time for tachyphylaxis to develop.
2. 50 mgWeek 1, oral — Erythromycin 50 mg orally, 30 minutes before meals. Start at the low end deliberately: higher doses increase cramping and diarrhoea substantially without proportionate emptying benefit, and at higher doses you drift toward antimicrobial exposure.
3. 250 mgWeeks 1-4, if 50 mg is insufficient — Up to 250 mg per dose, three or four times daily before meals. Deliberately kept below antimicrobial dosing. Beyond this the antimicrobial, resistance and interaction problems escalate faster than the prokinetic benefit.
4. —Week 2-4 onward — Stop. This is the actual key step in the ladder and the one people skip. Efficacy fades within 2-4 weeks through receptor downregulation. Cycle off for a few weeks to let motilin receptor expression recover, or reserve the drug entirely for flares. Continuous use guarantees loss of effect while retaining every risk.
5. 50 mgInvestigational — Camicinal (GSK962040) 50 mg once daily was the dose producing accelerated gastric emptying in phase 2 diabetic gastroparesis and improved enteral feed tolerance in critically ill patients. It is not approved and not obtainable.

• Motilin receptor (GPR38 / MLNR), cholinergic enteric neurons — No quantitative affinity resolved in this session for motilin, erythromycin or camicinal.

  Facilitates acetylcholine release from enteric cholinergic neurons, initiating phase III of the migrating motor complex. Produces strong propagating antral contractions and accelerated gastric emptying. Subject to rapid receptor downregulation with sustained stimulation — this is the class's defining limitation.

• Gastric antral smooth muscle — Not resolved.

  Direct contractile contribution alongside the neural effect. The cramping and nausea are the same mechanism as the therapeutic effect, which is why the therapeutic index here is inherently narrow.

• CYP3A4 (erythromycin only) — Potent inhibitor.

  Not a therapeutic target but the source of most of erythromycin's serious adverse events. Raises levels of simvastatin, lovastatin, ergot alkaloids, some calcium channel blockers, and many other substrates. This risk is fully present at prokinetic doses.

• hERG potassium channel (erythromycin only) — Not resolved to a number.

  QT prolongation. Additive with other QT-prolonging drugs and magnified by hypokalaemia or hypomagnesaemia — both of which are common in gastroparesis patients who vomit.

• The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients (Chapman et al.) Phase 2 · 2016

  Gastric emptying and glucose absorption in critically ill patients with enteral feed intolerance. One of the more clinically compelling results in this class.

• The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist camicinal in type 1 diabetes mellitus with slow gastric emptying (Hellström et al.) Phase 2 · 2016

  Pharmacodynamics, safety and pharmacokinetics of single-dose camicinal in type 1 diabetics with delayed gastric emptying.

• Manometric evaluation of the motilin receptor agonist camicinal (GSK962040) in humans (Deloose et al.) Mechanistic human study · 2018

  Effect of camicinal on human gastroduodenal motility measured by manometry — direct confirmation of the migrating motor complex mechanism in people rather than in animals.

Intravenous erythromycin accelerates gastric emptying within minutes — it is genuinely fast, which is why it works as a rescue and for feeding tube placement. Oral erythromycin's prokinetic effect appears within about an hour of a dose. And then the important part of the timeline: the effect typically fades over two to four weeks of continuous use through receptor downregulation. Plan the stop before you start.

The interaction that has become genuinely common and genuinely counterproductive is with GLP-1 receptor agonists. GLP-1 drugs slow gastric emptying — that is a substantial part of how they work. A motilin agonist exists to speed it up. Prescribing both is pharmacologically self-cancelling, and with GLP-1 use as widespread as it now is, this combination appears far more often than it should. If someone develops gastroparesis symptoms on semaglutide or tirzepatide, the answer is to address the GLP-1, not to add erythromycin. Metoclopramide plus erythromycin is sometimes used in refractory gastroparesis on the reasoning that dopamine antagonism and motilin agonism are different mechanisms. It can help. It also stacks side effects, and metoclopramide carries its own boxed warning for tardive dyskinesia while erythromycin prolongs QT — and metoclopramide can prolong QT too. This is a specialist combination, not a self-directed one. Statins are the interaction most likely to cause serious harm. Erythromycin's CYP3A4 inhibition raises simvastatin and lovastatin levels sharply, with real rhabdomyolysis risk. Switch to pravastatin or rosuvastatin, which are not CYP3A4-dependent, or hold the statin. Ondansetron is almost universal in this patient population and also prolongs QT. The combination with erythromycin is additive and is the single most common QT stacking scenario in gastroparesis care. Avoid with ergot alkaloids entirely.

This class is a case study in a sound mechanism failing to become a drug. Motilin physiology is well characterised, the receptor is identified, and erythromycin proves the mechanism works in humans. Three purpose-built agonists were developed. ABT-229 failed. Mitemcinal failed. Camicinal produced good phase 2 data across three separate studies and then stalled. Nothing has been approved for gastroparesis in this class, anywhere. Against metoclopramide, which is the only FDA-approved gastroparesis prokinetic in the US, erythromycin is faster and has no tardive dyskinesia risk, but it loses effect in weeks whereas metoclopramide does not. Metoclopramide has a boxed warning and a recommended duration limit; erythromycin has QT and interaction problems. Neither is good. Against domperidone, which is available in many countries but not the US, domperidone avoids the central side effects of metoclopramide but also prolongs QT. The honest comparison within this corpus is with the GLP-2 analogues. Both classes target gut motility and mucosal function. The GLP-2 programmes produced an approved drug and two more that hit their phase 3 endpoints. The motilin programmes produced nothing, largely because of tachyphylaxis. Same rigour, different biology, opposite outcome. And the contrast with GLP-1 agonists is worth stating plainly: the most successful gut motility drugs of the past decade slow the stomach down. The motilin class exists to speed it up, and it lost.

$10–$40/month. Generic oral erythromycin is inexpensive, on the order of tens of dollars per month at prokinetic doses in the US, though pricing varies by salt and formulation. Camicinal and mitemcinal have no price because they are not marketed. Native motilin has no therapeutic form. This is an approximate range for generic erythromycin, not a verified figure.

• ?No quantitative binding affinity at the motilin receptor was resolved for motilin, erythromycin or camicinal, so all affinity fields are qualitative.
• ?Erythromycin pharmacokinetic figures (half-life 1.5-2 hours, tmax around 2 hours) are standard textbook values that I did not verify against a label or primary source in this session; they also vary substantially by salt and formulation.
• ?Enrolment numbers for the three camicinal trials were not resolved and are left null.
• ?The Core record's specific claim about a 'camicinal phase 2 trial in diabetic gastroparesis' is supported by the Hellström single-dose study I verified, but I did not confirm a separate multi-dose phase 2 in that indication.
• ?The claim that tachyphylaxis is driven by motilin receptor downregulation is the standard mechanistic explanation and is well supported in the review literature, but I did not resolve a primary receptor-expression study.
• ?The role of interstitial cell of Cajal loss in limiting prokinetic efficacy is well established in the gastroparesis literature but is not cited to a specific source here.
• ?The Sanger review on motilin receptor agonists referenced in the Core record was not resolved to a PMID in this session.

• ACG Clinical Guideline: Gastroparesis Camilleri M, Kuo B, Nguyen L, et al., The American Journal of Gastroenterology, 2022 · PMID 35926490

  The authoritative guideline on where prokinetics sit in gastroparesis management, and the right starting point before deciding whether a motilin agonist is appropriate at all.

• The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial Chapman MJ, Deane AM, O'Connor SL, et al., Critical Care, 2016 · PMID 27476581

  The critical-care feeding data, arguably the strongest clinical result any purpose-built motilin agonist has produced.

• The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying Hellström PM, Tack J, Johnson LV, et al., British Journal of Pharmacology, 2016 · PMID 26924243

  Phase 2 gastric emptying data in diabetic gastroparesis, which is the indication the class was built for.

• Manometric evaluation of the motilin receptor agonist camicinal (GSK962040) in humans Deloose E, Verbeure W, Depoortere I, Tack J, Neurogastroenterology and Motility, 2018 · PMID 28782145

  Direct human manometry confirming the migrating motor complex mechanism, from the laboratory that has done most of the definitive human motilin physiology.

• The investigational drug camicinal for the treatment of gastroparesis Barshop K, Kuo B, Expert Opinion on Investigational Drugs, 2015 · PMID 25341626

  Review of camicinal's development, useful for understanding why the motilide programmes kept failing.

• UniProt P12872 (MOTI_HUMAN) — promotilin precursor; mature motilin residues 26-47 UniProtKB

  Sequence verification for native human motilin: FVPIFTYGELQRMQEKERNKGQ, 22 residues.